Rangeley Capital, LLC Lava Therapeutics Nv Transaction History
Rangeley Capital, LLC
- $116 Billion
- Q3 2025
A detailed history of Rangeley Capital, LLC transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Rangeley Capital, LLC holds 165,000 shares of LVTX stock, worth $273,900. This represents 0.22% of its overall portfolio holdings.
Number of Shares
165,000
Previous 27,073
509.46%
Holding current value
$273,900
Previous $35.7 Million
620.28%
% of portfolio
0.22%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding LVTX
# of Institutions
27Shares Held
7.26MCall Options Held
131KPut Options Held
51.8K-
Shay Capital LLC New York, NY2.55MShares$4.23 Million0.44% of portfolio
-
Redmile Group, LLC San Francisco, CA2.07MShares$3.44 Million0.36% of portfolio
-
Bml Capital Management, LLC Zionsville, IN1.97MShares$3.27 Million2.81% of portfolio
-
Gts Securities LLC New York, NY200KShares$332,0000.01% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA65KShares$107,9000.0% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $42.8M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...